Phase III data shows Imbruvica (ibrutinib )superior to chlorambucil in chronic lymphocytic leukemia and small lymphocytic lymphoma - Janssen/Pharmacyclics
Data from the investigational, randomized, multi-center, open-label Phase III RESONATE-2 (PCYC-1115) clinical trial show Imbruvica (ibrutinib), from Janssen/Pharmacyclics, was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older. Ibrutinib significantly prolonged progression-free survival (PFS), the study's primary endpoint, and overall survival (OS), a key secondary endpoint, and also improved other hematologic measures.
Notably, ibrutinib was associated with a 98 percent OS rate versus 85 percent for chlorambucil at 24 months. These data will be presented at the 2015 American Society of Hematology meeting and simultaneously published in The New England Journal of Medicine.
Related news and insights
Anavex Life Sciences Corp. announced positive topline results from its Phase IIb/III ANAVEX2-73-AD-004 clinical trial of oral ANAVEX2 73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).
Vaxxinity announced today that its next generation UB 612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase III trial.